NRSN - NeuroSense Therapeutics Ltd
IEX Last Trade
0.8887
0.129 14.482%
Share volume: 1,356,232
Last Updated: Fri 30 Aug 2024 09:59:53 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.76
0.13
16.93%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
7.23%
1 Month
23.41%
3 Months
-17.59%
6 Months
-50.56%
1 Year
-7.20%
2 Year
-55.28%
Key data
Stock price
$0.89
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.40 - $2.33
52 WEEK CHANGE
-$0.03
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO:
Region: US
Website: neurosense-tx.com
Employees: 18
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: neurosense-tx.com
Employees: 18
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
advancing research, development and therapy for als. neurosense therapeutics is a biotech company focusing on the development of mirnas as a novel treatment for als. currently preparing for a first clinical study in patients in usa
Recent news